Rgenta Therapeutics is a technology company.
Rgenta Therapeutics has raised $90.0M across 3 funding rounds.
Rgenta Therapeutics has raised $90.0M in total across 3 funding rounds.
Rgenta Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, focused on developing a pipeline of oral RNA-targeting small molecule medicines.[1][2][5] The company targets "undruggable" diseases by harnessing genomic data to identify precise RNA sites and regulatory proteins, enabling small molecules to modulate RNA function and prevent production of disease-associated proteins, with an initial emphasis on oncology and neurological disorders.[2][4] It serves patients with unmet medical needs by advancing therapies where traditional protein-targeting approaches fail, and demonstrates growth momentum through clinical-stage programs, partnerships like Blood Cancer United since June 2023, and collaborations with investors, universities, and institutions.[3][4]
Rgenta Therapeutics was founded in 2018 by Simon Xi, Ph.D. (Co-founder and CEO), Travis Wager, Ph.D. (Co-founder, President, and CSO), and Zhiping Weng, Ph.D. (Co-founder and Head of Scientific Advisory Board), all experts in RNA-targeting and drug discovery.[3][5] The idea emerged from leveraging genomic data to revolutionize drug discovery for hard-to-treat targets, building on the founders' backgrounds in biotechnology and RNA modulation to create a platform for oral small molecules that engage RNA and its regulators with high specificity.[2] Early traction includes establishing a strong leadership team, a prestigious Scientific Advisory Board with advisors like Philip Zamore, Ph.D., and Sarah Tabrizi, M.D., Ph.D., and partnerships such as with Blood Cancer United in June 2023 to accelerate oncology-focused development.[3][4]
Rgenta rides the RNA therapeutics trend, capitalizing on advances in genomic sequencing and AI-driven target identification to unlock RNA as a druggable modality beyond mRNA vaccines or ASOs.[2] Timing is ideal amid rising demand for oral small molecules in oncology and neurology, where protein degradation and undruggable targets represent multi-billion-dollar markets strained by injectable biologics' limitations.[1][4] Favorable forces include exploding genomic datasets, improved computational modeling for RNA structures, and investor interest in precision medicine, positioning Rgenta to influence the ecosystem through partnerships that de-risk pipelines and expand RNA-targeting adoption.[3]
Rgenta is poised to advance its clinical pipeline into key readouts for oncology and neurology indications, potentially yielding first-in-class oral RNA modulators by expanding collaborations and leveraging its platform for broader therapeutic areas.[1][3] Trends like AI-enhanced genomics and combination therapies with PROTACs will shape its trajectory, amplifying impact as RNA targeting matures into a mainstream paradigm. Its influence may evolve from niche innovator to ecosystem leader, redefining druggability and delivering transformative options for undruggable diseases—echoing its mission to make the impossible routine in biotech.[2]
Rgenta Therapeutics has raised $90.0M in total across 3 funding rounds.
Rgenta Therapeutics's investors include Boehringer Ingelheim Venture Fund, Vivo Capital, ALSA Ventures, AMR Action Fund.
Rgenta Therapeutics has raised $90.0M across 3 funding rounds. Most recently, it raised $52.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $52.0M Series A | Boehringer Ingelheim Venture Fund, Vivo Capital | |
| May 1, 2021 | $18.0M Seed | Vivo Capital | |
| Apr 1, 2020 | $20.0M Seed | ALSA Ventures, AMR Action Fund |